These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 36900247)

  • 1. Is CIS a Contraindication to Hyperthermic Intravesical Chemotherapy (HIVEC) after BCG-Failure?
    Anastay V; Baboudjian M; Masson-Lecomte A; Lebacle C; Chamouni A; Irani J; Tillou X; Waeckel T; Monges A; Duperron C; Gravis G; Walz J; Lechevallier E; Pignot G
    Cancers (Basel); 2023 Feb; 15(5):. PubMed ID: 36900247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term efficacy of hyperthermic intravesical chemotherapy for BCG-unresponsive non-muscle invasive bladder cancer.
    Pijpers OM; Hendricksen K; Mostafid H; de Jong FC; Rosier M; Mayor N; de Jong JJ; Boormans JL
    Urol Oncol; 2022 Feb; 40(2):62.e13-62.e20. PubMed ID: 34470725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of hyperthermic intravesical chemotherapy (HIVEC) in patients with non-muscle invasive bladder cancer after BCG failure.
    Pignot G; Baboudjian M; Lebacle C; Chamouni A; Lechevallier E; Irani J; Tillou X; Waeckel T; Monges A; Doisy L; Walz J; Gravis G; Mourey E; Duperron C; Masson-Lecomte A
    World J Urol; 2023 Nov; 41(11):3195-3203. PubMed ID: 36811732
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of systemic inflammatory markers on the response to Hyperthermic IntraVEsical Chemotherapy (HIVEC) in patients with non-muscle-invasive bladder cancer after bacillus Calmette-Guérin failure.
    Chiancone F; Fabiano M; Carrino M; Fedelini M; Meccariello C; Fedelini P
    Arab J Urol; 2021 Jan; 19(1):86-91. PubMed ID: 33763253
    [No Abstract]   [Full Text] [Related]  

  • 5. Recirculating hyperthermic intravesical chemotherapy with mitomycin C (HIVEC) versus BCG in high-risk non-muscle-invasive bladder cancer: results of the HIVEC-HR randomized clinical trial.
    Guerrero-Ramos F; González-Padilla DA; González-Díaz A; de la Rosa-Kehrmann F; Rodríguez-Antolín A; Inman BA; Villacampa-Aubá F
    World J Urol; 2022 Apr; 40(4):999-1004. PubMed ID: 35037963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyperthermic intravesical chemotherapy with mitomycin-C for the treatment of high-risk non-muscle-invasive bladder cancer patients.
    Conroy S; Pang K; Jubber I; Hussain SA; Rosario DJ; Cumberbatch MG; Catto JWF; Noon AP
    BJUI Compass; 2023 May; 4(3):314-321. PubMed ID: 37025474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of HIVEC in patients with high-risk non-muscle invasive bladder cancer who are contraindicated to BCG and in patients who fail BCG therapy.
    Doisy L; Cimier A; Adypagavane A; Walz J; Marquette T; Maubon T; Rybikowski S; Fakhfakh S; Loverde K; Mottet N; Irani J; Lechevallier E; Rossi D; Gravis G; Pignot G
    Int J Hyperthermia; 2021; 38(1):1633-1638. PubMed ID: 34775896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adverse events of hyperthermic intravesical chemotherapy for non-muscle invasive bladder cancer patients.
    Thomsen JA; Nielsen Dominiak H; Lindgren MS; Jensen JB
    Scand J Urol; 2021 Aug; 55(4):281-286. PubMed ID: 34124993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hyperthermic Intravesical Chemotherapy for BCG Unresponsive Non-Muscle Invasive Bladder Cancer Patients.
    de Jong JJ; Hendricksen K; Rosier M; Mostafid H; Boormans JL
    Bladder Cancer; 2018 Oct; 4(4):395-401. PubMed ID: 30417050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes and complications of Hyperthermic IntraVesical Chemotherapy using mitomycin C or epirubicin for patients with non-muscle invasive bladder cancer after bacillus Calmette-Guérin treatment failure.
    Chiancone F; Fabiano M; Fedelini M; Meccariello C; Carrino M; Fedelini P
    Cent European J Urol; 2020; 73(3):287-294. PubMed ID: 33133655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparing adverse effects, short term outcomes, and cost implications of hyperthermic intravesical chemotherapy with Mitomycin-C and intravesical bacillus Calmette-Guerin instillation (Moscow-I strain) in the management of intermediate and high-risk nonmuscle invasive bladder cancer.
    Thyavihally YB; Waigankar SS; Dev P; Asari A; Pednekar AP; Athikari N; Raut A; Khandekar A; Badlani N
    Urol Ann; 2021; 13(4):424-430. PubMed ID: 34759657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-Term Experience with Hyperthermic Chemotherapy (HIVEC) Using Mitomycin-C in Patients with Non-Muscle Invasive Bladder Cancer in Spain.
    Plata A; Guerrero-Ramos F; Garcia C; González-Díaz A; Gonzalez-Valcárcel I; de la Morena JM; Díaz-Goizueta FJ; Del Álamo JF; Gonzalo V; Montero J; Sousa-Escandón A; León J; Pontones JL; Delgado F; Adriazola M; Pascual Á; Calleja J; Ruano A; Martínez-Piñeiro L; Angulo JC
    J Clin Med; 2021 Oct; 10(21):. PubMed ID: 34768625
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multi-institutional retrospective study of hyperthermic plus intravesical chemotherapy versus intravesical chemotherapy treatment alone in intermediate and high risk nonmuscle-invasive bladder cancer.
    Ruan Q; Ding D; Wang B; He C; Ren X; Feng Z; Pang Z; Wang J; Zhang X; Tang H; Wang J; He Q; Lei Z; Liao Q; Luo J; Cui S
    Cancer Biol Med; 2021 Feb; 18(1):308-317. PubMed ID: 33628603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant intravesical treatment in patients with intermediate and high-risk non-muscle-invasive bladder cancer with BCG versus MMC applied with COMBAT or EMDA. Results of a prospective study.
    Arrabal Polo MÁ; Melgarejo Segura MT; Yáñez Castillo Y; Morales Martínez A; Pareja Vílchez M; Arrabal Martín M
    J Cancer Res Clin Oncol; 2023 Aug; 149(10):7453-7459. PubMed ID: 36952006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conductive hyperthermic chemotherapy versus electromotive drug administration of mitomycin C as intravesical adjuvant treatment of patients with intermediate or high-risk non-muscle invasive bladder cancer.
    Melgarejo Segura MT; Morales Martínez A; Yáñez Castillo Y; Arrabal Polo MÁ; Gómez Lechuga P; Pareja Vílchez M; Arrabal Martín M
    Urol Oncol; 2023 Feb; 41(2):109.e1-109.e8. PubMed ID: 36379812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Safety of Hyperthermic IntraVEsical Chemotherapy (HIVEC) for BCG Unresponsive Non-Muscle Invasive Bladder Cancer Patients].
    Marquette T; Walz J; Rybikowski S; Maubon T; Branger N; Fakhfakh S; Verde KL; Dermeche S; Gravis G; Pignot G
    Prog Urol; 2020 Jan; 30(1):35-40. PubMed ID: 31787540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical trial of high dose hyperthermic intravesical mitomycin C for intermediate and high-risk non-muscle invasive bladder cancer during BCG shortage.
    Grimberg DC; Dudinec J; Shah A; Inman BA
    Urol Oncol; 2021 Aug; 39(8):498.e13-498.e20. PubMed ID: 33485761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Using Grade of Recurrent Tumor to Guide Further Therapy While on Bacillus Calmette-Guerin: Low-grade Recurrences Are not Benign.
    Li R; Metcalfe MJ; Tabayoyong WB; Guo CC; Nogueras González GM; Navai N; Grossman HB; Dinney CP; Kamat AM
    Eur Urol Oncol; 2019 May; 2(3):286-293. PubMed ID: 31200843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of different adjuvant intravesical therapy methods on tumor biology in patients with high-risk non-muscle-invasive bladder cancer.
    Kostyev F; Bondar O; Chystiakov R; Lysenko V; Stavnychyi O; Varbanets V
    Cent European J Urol; 2021; 74(4):496-502. PubMed ID: 35083068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016.
    Babjuk M; Böhle A; Burger M; Capoun O; Cohen D; Compérat EM; Hernández V; Kaasinen E; Palou J; Rouprêt M; van Rhijn BWG; Shariat SF; Soukup V; Sylvester RJ; Zigeuner R
    Eur Urol; 2017 Mar; 71(3):447-461. PubMed ID: 27324428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.